Wirkstoffe & Arzneimittelsicherheit

Gegenanzeigen · Elonva

Elonva 100 micrograms solution for injection Elonva 150 micrograms solution for injection · Abschnitt 4.3 · PDF-Seite 4

HOS-121990 · Präparat HOS-095457

 Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.  Tumours of the ovary, breast, uterus, pituitary or hypothalamus.  Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause.  Primary ovarian failure.  Ovarian cysts or enlarged ovaries.  Fibroid tumours of the uterus incompatible with pregnancy.  Malformations of the reproductive organs incompatible with pregnancy.  Risk factors for OHSS: o A history of Ovarian Hyperstimulation Syndrome (OHSS). o A previous COS cycle that resulted in more than 30 follicles ≥ 11 mm measured by ultrasound examination. o A basal antral follicle count > 20. o Polycystic ovarian syndrome (PCOS).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.